KALA BIO, Inc. (KALA) Stock Score, Valuation & Financial Research

KALA BIO, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KALA

KALA BIO, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.36. These figures are a research snapshot, not a buy or sell recommendation.

What KALA BIO, Inc. does

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

KALA BIO, Inc. is a biopharmaceutical company currently transitioning its business model to focus on the development of Researgency.ai, an enterprise AI tool designed for biopharmaceutical teams. The company also leverages its historical clinical data and expertise in ophthalmic diseases to provide insights and services, while exploring commercial opportunities such as the distribution of genetic testing and screening programs.

Products and services

  • The company's primary product under development is Researgency.ai, an enterprise AI platform for clinical research. Additionally, the company holds legacy clinical data from prior ophthalmic programs and has entered into agreements for the distribution of genetic testing and screening programs in the ophthalmology sector.

Brands and product families

  • Researgency.ai — An enterprise AI tool for biopharmaceutical teams currently under development. Source

Customer types

Biopharmaceutical companies.

Business relationships and partnerships

  • Virotek — A commercial collaboration where KALA acts as the exclusive distributor and reseller of a genetic testing and screening program for ophthalmology in the United States, with net profits split equally between the parties. Source

Business strengths to evaluate

  • Proprietary legacy clinical trial data Source

Business risks and research considerations

  • History of operating losses and accumulated deficits Source
  • Risks associated with the development and commercialization of new AI technology Source

Sources: Company research source · Researgency.ai · Virotek

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KALA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.36
Market capitalization:
7.04M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -10.08M
Free cash flow:
USD -32.01M
Cash:
USD 229K
Total debt:
USD 0.00
EPS:
USD -81.82

What stands out

  • Free cash flow is USD -32.01M, negative for the stored period.
  • The balance sheet shows USD 229K of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 229K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KALA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can KALA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is KALA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for KALA to reach sustainable profitability?
  • What does the current share basis reconciled warning mean for the reliability or interpretation of KALA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research KALA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.